Methodology: Two hundred T2DM patients on standard glucose lowering agents and who may be on lipid and blood pressure lowering agents were followed up for 2 years for improvement in CV risk markers like BMI, HbA1c, systolic blood pressure(S-BP), diastolic BP(D-BP), total cholesterol(TC), HDL, non-HDL, LDL, triglycerides(TG), cholesterol remnant(CR), highly-sensitive CRP(hsCRP), serum creatinine(Cr) and eGFR. T2DM patients with recent history of re-vascularisation or any major surgery were excluded. At the end of 2 years, NT-proBNP was measured as an assessment tool for residual CV risk. Those with higher NT-proBNP(>=125) were identified and patient level characteristics as described above were analysed and compared to patients with NT-proBNP <125. Data was analysed using SPSS version 20, represented as Mean + 2(SD) with 95% CI, descriptive statistics and independent t test was used and p-value of less than 0.was considered statically-significant (Si)>.
Results: Baseline characteristics of patients with elevated NT-pro-BNP were: 40(54.05%) males and 34 (45.9%) females, mean age 63.54 ± 10.61 years, mean age since diagnosis 13.5 ± 7.3 years and mean BMI 29.41 ± 5.32 kg/m2. The mean values at the end of 2 years in patients with elevated NT-proBNP were: HbA1c 6.7 ± 1.13, S-BP 132.24 ± 27.5, D-BP 72.93 ± 17.14, TC 140.22 ± 48.98, LDL 70.57 ± 32.95, TG 131.13 ± 91.37, HDL 38.8 ± 13.02, non-HDL 90.18 ± 37.44, CR 23.11 ± 17.7, Cr 1.01 ± 0.29, eGFR 79.29 ± 25.2, hsCRP 4.09 ± 0.51,. There was Si difference seen with regard to Age(p-0.039), weight(p-0.015), D-BP(p-0.016), non-HDL(p-0.05), Cr(p-0.001), eGFR(0.001) at 2 years in patients with elevated NT proBNP compared to those with normal levels.
Conclusion: Patients with elevated NT-proBNP were older, had greater D-BP, TC, LDL, TG, non HDL, CR, Cr and weight and lower HDL and eGFR compared to patients without elevated NT pro BNP at 2 year.
V. Gupta: None. V. Teli: None.